HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

539.840

-20.829-3.72%

Number of Gainers:1

Number of Losers:32

Number of Flat:1

PE:- -

High:559.501

Open:559.501

Low:529.501

Close:560.669

Volume:112.92M

Turnover:2.31B

Market Cap:345.69B

Float Cap:307.20B

Loading ...

BRIEF-Sinomab Bioscience Posts Loss For Year Rmb105.0 Million

From 22% Plunge to 1.5% Uptick: Has China's Pharma Distribution Leader Stabilized After Management Overhaul?

SINOMAB BIO-B (03681) Reports Significant Narrowing of Losses in 2025, Major Strides in Pipeline Development and Commercialization

SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million

SinoMab reports SM17 Phase 1b atopic dermatitis results with 91.7% NRS-4 response rate

ZYLOXTB (02190) Spends HK$3.405 Million on Share Buyback

Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each

JACOBIO-B Allocates HK$499,800 for Share Buyback on March 23

Kintor Pharmaceutical postpones board meeting to approve annual results

Kehua Bio's Subsidiary Secures Medical Device Registration Certificate

Remegen's ADC Therapy Disitamab Vedotin Secures Approval for New Breast Cancer Indication

SHANDONG XINHUA (00719) Unit Secures Drug Registration Certificate for Ibuprofen Granules

Hua Medicine to relocate Hong Kong principal office to Suite 1701, 8 Queen's Road East on March 23, 2026

KINTOR PHARMA-B Shares Extend Decline, Dropping Over 9% Amid Ongoing "Whitening Ingredient" Dispute

Immunotech Biopharm's 2025 Loss Widens

MT Newswires Live

Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults

Kaisa Health Shares Surge Over 40% Against Market Trend on Planned Acquisition of Qinghai Pharmaceutical

BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million

Everest Med Enters Asset Purchase Agreement with Jixing Pharmaceutical Hong Kong

Everest Medicines unit to acquire etripamil nasal spray assets for up to USD 50 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":539.83997,"timestamp":1774253287512,"preClose":560.66925,"halted":0,"volume":112922532,"delay":0,"changeRate":-0.037151,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-20.829285,"latestTime":"03-23 16:00:00","open":559.50055,"high":559.50055,"low":529.50085,"amount":2306733960,"amplitude":0.053507,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"pbRate":5.065234,"peRate":-56.829124,"turnoverRate":0.004002,"increases":1,"decrements":31,"flats":1,"marketCap":345688491520,"floatMarketCap":307200402224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":559.50055,"amplitude":0.053507,"preClose":560.66925,"low":529.50085,"pbRate":"5.065234","latestPrice":539.83997,"volume":112922532,"delay":0,"open":559.50055,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":575.339,"twentyDayClose":574.827,"sixtyDayClose":595.179,"secType":"PLATE","market":"HK","turnoverRate":0.004002,"peRate":-56.829124,"marketCap":345688491520,"floatMarketCap":307200402224,"timestamp":1774253287512,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":1,"down":32,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621128707","title":"BRIEF-Sinomab Bioscience Posts Loss For Year Rmb105.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621128707","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621128707?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:25","pubTimestamp":1774279556,"startTime":"0","endTime":"0","summary":"BRIEF-Sinomab Bioscience Posts Loss For Year Rmb105.0 MillionMarch 23 (Reuters) - SinoMab BioScience Ltd 3681.HK:LOSS FOR YEAR RMB105.0 MILLIONFurther company coverage: 3681.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"1139304821","title":"From 22% Plunge to 1.5% Uptick: Has China's Pharma Distribution Leader Stabilized After Management Overhaul?","url":"https://stock-news.laohu8.com/highlight/detail?id=1139304821","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139304821?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:01","pubTimestamp":1774278112,"startTime":"0","endTime":"0","summary":"In the latest wave of industry competition and realignment, few sectors can survive by relying solely on past achievements. The transition from scale leadership to quality leadership is a challenging...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","BK1161","BK1574"],"gpt_icon":0},{"id":"1108253845","title":"SINOMAB BIO-B (03681) Reports Significant Narrowing of Losses in 2025, Major Strides in Pipeline Development and Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=1108253845","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108253845?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:54","pubTimestamp":1774277666,"startTime":"0","endTime":"0","summary":"SINOMAB BIO-B (03681) announced its 2025 financial results, with other income and gains reaching approximately RMB 29.271 million, a year-on-year increase of 2.84 times. Research and development...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1161","BK1574"],"gpt_icon":0},{"id":"2621351704","title":"SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621351704","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621351704?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:17","pubTimestamp":1774275473,"startTime":"0","endTime":"0","summary":"SinoMab published an annual results announcement for the year ended Dec. 31, 2025, including a change in use of proceeds.Loss for the year was RMB105.0 million, a 43.3% decrease.Total funding available to use was RMB351.5 million, more than doubled, reflecting share subscription proceeds and partially offset by bank borrowing repayments, operating cash outflows and capital expenditures.Net cash used in operating activities was RMB70.48 million, while net cash from financing activities was RMB329.39 million.Business updates included positive Phase 1b topline results for SM17 in atopic dermatitis, initiation of a Phase 1 bridging study for subcutaneous administration, and NMPA acceptance of an SM17 IND for inflammatory bowel disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9DY9rX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1161","BK1574"],"gpt_icon":0},{"id":"2621043567","title":"SinoMab reports SM17 Phase 1b atopic dermatitis results with 91.7% NRS-4 response rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621043567","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621043567?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:17","pubTimestamp":1774275460,"startTime":"0","endTime":"0","summary":"SinoMab reported clinical topline results for SM17 in moderate-to-severe atopic dermatitis, positioning the program for a potential phase 2 start as early as mid-2026.The company said the results support differentiation in itch relief and skin recovery versus IL-4/IL-13 biologics, while also citing a safety profile that may broaden patient eligibility compared with JAK inhibitors.An IND for SM17 in inflammatory bowel disease was accepted by China’s drug review center and later approved, expanding the asset’s commercial scope beyond dermatology.Funding raised via share subscriptions totaled HKD 493.7 million, which the company said supports continued clinical development and commercialization preparations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6lgK6n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"1138129466","title":"ZYLOXTB (02190) Spends HK$3.405 Million on Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=1138129466","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138129466?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:19","pubTimestamp":1774268367,"startTime":"0","endTime":"0","summary":"On March 23, 2026, ZYLOXTB (02190) announced it had repurchased 150,000 of its shares at a total cost of HK$3.405 million.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1587","BK1583","BK1574","02190"],"gpt_icon":0},{"id":"1163864908","title":"Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1163864908","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163864908?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:22","pubTimestamp":1774264934,"startTime":"0","endTime":"0","summary":"On March 19, Wellington Management Group LLP purchased an additional 3.82 million shares of GENFLEET-B (02595) at HK$25.5 per share, totaling approximately HK$97.50 million. Following this...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02595","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"1120687926","title":"JACOBIO-B Allocates HK$499,800 for Share Buyback on March 23","url":"https://stock-news.laohu8.com/highlight/detail?id=1120687926","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120687926?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:18","pubTimestamp":1774261111,"startTime":"0","endTime":"0","summary":"JACOBIO-B (01167) announced that on March 23, 2026, the company repurchased 80,100 shares at a total cost of HK$499,800.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2621771945","title":"Kintor Pharmaceutical postpones board meeting to approve annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621771945","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621771945?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:39","pubTimestamp":1774258792,"startTime":"0","endTime":"0","summary":"A Kintor board meeting to consider and approve the company’s annual results will be held on March 30, 2026.The meeting date was changed from March 26, 2026 to March 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8nGCPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"1108868787","title":"Kehua Bio's Subsidiary Secures Medical Device Registration Certificate","url":"https://stock-news.laohu8.com/highlight/detail?id=1108868787","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108868787?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:12","pubTimestamp":1774257144,"startTime":"0","endTime":"0","summary":"Shanghai Kehua Bio-Engineering Co.,Ltd. (002022.SZ) has announced that its subsidiary, Xi'an Tianlong Technology Co., Ltd., has obtained a medical device registration certificate issued by the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","BK1583","BK0046","BK0028","BK1574","BK0239","BK1222","002022","BK1100","09997","BK0188","09996"],"gpt_icon":0},{"id":"1117231507","title":"Remegen's ADC Therapy Disitamab Vedotin Secures Approval for New Breast Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1117231507","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117231507?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:52","pubTimestamp":1774255945,"startTime":"0","endTime":"0","summary":"Remegen Co., Ltd. (688331.SH) has announced that it recently obtained a drug registration certificate from the National Medical Products Administration. The new indication application for disitamab...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","688331","BK1583","LU2488822045.USD","09995","BK0239","LU2328871848.SGD","LU2148510915.USD","BK1574","LU1064131003.USD","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"1111654461","title":"SHANDONG XINHUA (00719) Unit Secures Drug Registration Certificate for Ibuprofen Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=1111654461","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111654461?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:44","pubTimestamp":1774255472,"startTime":"0","endTime":"0","summary":"SHANDONG XINHUA PHARMACEUTICAL (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ibuprofen Granules...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1515","BK1191","00719"],"gpt_icon":0},{"id":"2621277515","title":"Hua Medicine to relocate Hong Kong principal office to Suite 1701, 8 Queen's Road East on March 23, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621277515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621277515?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254661,"startTime":"0","endTime":"0","summary":"Hua Medicine will relocate its principal place of business in Hong Kong effective March 23, 2026.The new office will be in Wanchai, moving from Hennessy Road to Queen's Road East.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hua Medicine published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8hvNs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"1173386211","title":"KINTOR PHARMA-B Shares Extend Decline, Dropping Over 9% Amid Ongoing \"Whitening Ingredient\" Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=1173386211","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173386211?lang=en_us&edition=fundamental","pubTime":"2026-03-23 14:06","pubTimestamp":1774245984,"startTime":"0","endTime":"0","summary":"KINTOR PHARMA-B (09939) fell more than 9% again, bringing its cumulative decline over the past three trading sessions to nearly 35%. At the time of writing, the stock was down 9% to HK$2.73, with a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1161","BK4588","VXUS","BK1515","BK1574","BK4585"],"gpt_icon":0},{"id":"2621729893","title":"Immunotech Biopharm's 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2621729893","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621729893?lang=en_us&edition=fundamental","pubTime":"2026-03-23 11:52","pubTimestamp":1774237920,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm  booked 230.8 million yuan in attributable loss for 2025, widening from a loss of 186.9 million yuan in 2024, according to a Hong Kong bourse filing Friday.Shares of the cancer therapy developer fell by over 1% in morning trade Monday.Loss per share was 0.42 yuan, compared with 0.35 yuan in the prior year.The company did not generate revenue during the year. Other income amounted to 20.5 million yuan, compared with 33.8 million yuan in 2024.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2621726337","title":"Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2621726337","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621726337?lang=en_us&edition=fundamental","pubTime":"2026-03-23 11:15","pubTimestamp":1774235736,"startTime":"0","endTime":"0","summary":"Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 , a TSLP-targeting monoclonal antibody.The study enrolled 50 healthy adults across five cohorts , with eight participants receiving HBM9378 and two receiving placebo in each cohort.Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.Pharmacokinetic results included a median Tmax range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.Anti-drug antibodies were reported in 5%  of participants who received HBM9378, with no clinical correlate or impact on drug exposure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2CC4jY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02142","BK1161"],"gpt_icon":0},{"id":"1140536017","title":"Kaisa Health Shares Surge Over 40% Against Market Trend on Planned Acquisition of Qinghai Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1140536017","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140536017?lang=en_us&edition=fundamental","pubTime":"2026-03-23 10:20","pubTimestamp":1774232437,"startTime":"0","endTime":"0","summary":"Kaisa Health (00876) saw its shares surge more than 40% against the broader market trend. At the time of writing, the stock was up 30%, trading at HK$0.117 with a turnover of HK$4.9696 million. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","00876","BK1222","01477","BK1191","BK4588","BK1574","VXUS"],"gpt_icon":0},{"id":"2621425747","title":"BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621425747","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621425747?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:29","pubTimestamp":1774225753,"startTime":"0","endTime":"0","summary":"BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 MillionMarch 23  - Everest Medicines Ltd 1952.HK:UNIT TO BUY ASSETS FOR UP TO $50 MILLIONASSETS REFERS TO PHARMACEUTICAL PRODUCTS THAT USES DEVICE TO DELIVER ETRIPAMIL BY NASAL SPRAYFurther company coverage: 1952.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40900N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"1145799286","title":"Everest Med Enters Asset Purchase Agreement with Jixing Pharmaceutical Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1145799286","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145799286?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:08","pubTimestamp":1774224509,"startTime":"0","endTime":"0","summary":"Everest MED (01952) has announced that on March 23, 2026, the buyer, a wholly-owned subsidiary of the company, entered into an asset purchase agreement with the seller, Jixing Pharmaceutical Hong...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","01952","BK1161"],"gpt_icon":0},{"id":"2621723742","title":"Everest Medicines unit to acquire etripamil nasal spray assets for up to USD 50 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621723742","media":"Reuters","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621723742?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:58","pubTimestamp":1774223924,"startTime":"0","endTime":"0","summary":"Everest Medicines’ wholly owned Singapore subsidiary signed an asset purchase agreement to acquire intellectual property and product inventory related to an etripamil nasal spray product in China.Transaction consideration is up to USD 50.0 million, comprising USD 30.0 million upfront and up to USD 20.0 million in development milestones.Milestones include USD 15.0 million tied to NMPA NDA approval for paroxysmal supraventricular tachycardia and USD 3.0 million tied to NMPA acceptance of a marketing authorization application for a localized version.As part of the closing, the buyer will assume certain obligations under assigned contracts, including up to USD 92.0 million in sales milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL2f33kd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","01952","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":1,"totalSize":271,"code":"91000000","status":"200"}]}}